Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

(2014) J. P. Arm et al.   CLINICAL AND EXPERIMENTAL ALLERGY

A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma

(2014) E Suzanne Cohen et al.   mAbs

Omalizumab in Asthma: An Update on Recent Developments

(2014) Marc Humbert et al.   Journal of Allergy and Clinical Immunology-In Practice

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

(2013) Marcus Maurer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

(2012) Deborah L. Mortensen et al.   mAbs

Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

(2011) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IgE, mast cells, basophils, and eosinophils

(2010) Kelly D. Stone et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

(2009) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update

(2009) Stephen Holgate et al.   RESPIRATORY MEDICINE

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

(2008) Wendy S. Putnam et al.   AAPS Journal